Group PACBT for Depression
Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Semel Institute
-
Principal Investigator:
- Marc Weintraub, PhD
-
Contact:
- Shelby Grody
- Phone Number: 3108254354
- Email: UCLAPAT@mednet.ucla.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages 21-60,
- Fluent in English
- Able to swallow capsules,
- Meets for a current major depressive episode or a history of major depressive episodes based on the DSM-5 criteria (American Psychiatric Association, 2013),
- Active current depressive symptoms (i.e., scores >16 on the Hamilton-Depression Rating Scale covering the prior 2 weeks; Hamilton, 1986),
- Have an identified support person (i.e., trusted adult friend or relative) who can pick up the individual from UCLA Semel Institute and drive individual home following psilocybin sessions,
- For women of child-bearing potential - using one form of highly effective contraception (e.g., oral contraceptive pill) and willingness to continue contraceptive use for duration of study. Must be willing to take on-site pregnancy tests.
- Agree to refrain from any psychoactive drug (including alcohol) within 24 hours of each drug session and during the drug sessions. Participants will be allowed to consume their usual amount of caffeine prior to and after the drug sessions.
- Agree to not take any PRN medications on the mornings of the drug sessions
- Has been medically cleared for the study by a physician
- Participants must remain on anti-hypertensive medications if prescribed previously to manage hypertension
Exclusion Criteria:
- A personal or family history (first-degree) of psychosis or mania
- Resting blood pressure above 140 systolic, 90 diastolic or heart rate > 90 beats per minute (averaged across four separate measurements)
- Meeting criteria for a DSM-5 cluster B personality disorder (narcissistic, histrionic, borderline, antisocial personality disorder),
- Active suicidality (i.e., HAM-D item 3 score of greater than 3) or other psychiatric disturbance requiring acute treatment
- Current use of antidepressants or other serotonergic-affecting substances (e.g., St. John's Wort and 5-hydroxytryptophan), lithium, or efavirenz [regardless of whether the drug(s) is/are prescribed for MDD or other conditions]
- Current use of opioids (e.g., codeine, fentanyl, hydrocodone, meperidine, tramadol)
- Currently receiving cognitive behavioral therapy,
- Any of the following cardiovascular conditions: uncontrolled hypertension, coronary artery disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, tachycardia, artificial heart valve, a clinically significant screening ECG abnormality, or any other significant cardiovascular condition
- QTc interval measurement of > 450 ms in males or > 460 ms in females as measured by the baseline ECG
- A history of stroke or Transient Ischemic Attack (TIA)
- Epilepsy or history of seizures
- Insulin-dependent diabetes
- Meeting criteria for a DSM-5 substance abuse or dependence within prior 6 months (including for nicotine and cannabis)
- Positive urine drug screen for illicit substances (not including cannabis)
- Use of other psychedelics or ketamine within prior 12 months
- Adverse prior reaction to a 5-HT2A receptor agonist psychedelic agent
- Pregnant, trying to get pregnant, or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group PACBT
12 sessions of PA-CBT (as manualized by our research team; Weintraub et al., 2023) and two administrations of psilocybin, administered orally (a 10mg dose followed by a 25mg dose one month later), all of which will be delivered in a group format whereby participants receive the treatments together and simultaneously
|
Two administrations of psilocybin, administered orally (a 10mg dose followed by a 25mg dose one month later)
12 sessions of PA-CBT (as manualized by our research team; Weintraub et al., 2023)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment acceptability
Time Frame: 4 months (Baseline to Post-treatment)
|
Treatment acceptability as measured by the participant on the Client Satisfaction Questionnaire-8.
Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
|
4 months (Baseline to Post-treatment)
|
|
Feasibility as measured by participant retention
Time Frame: 4 months
|
Participant retention over the treatment
|
4 months
|
|
Hamilton Depression Rating Scale
Time Frame: 7 months (Baseline to end of study)
|
Depressive symptom severity scored from 0-53, with larger values indicating greater depressive severity
|
7 months (Baseline to end of study)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 25-0602
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.